View More View Less
  • 1 I. Gyermekklinika, Semmelweis Egyetem, Magyar Tudományos Akadémia és Semmelweis Egyetem Gyermekgyógyászati és Nefrológiai Kutatócsoportja, 1083 Budapest, Bókay u. 53/54.
Restricted access

Az egyénre szabott terápia az emlőtumorok közeljövőbeli klinikai szisztémás kezelésének alapja lesz. Ehhez a tumorok hatékonyabb jellemzése, pontosabb prediktív és prognosztikus információk nyerése szükséges, amelyet monogénes (ER, PR, HER-2, stb.), vagy multigénes tesztek alkalmazása tesz lehetővé. Multigénes tesztek segítségével különböző klinikai problémákra tudunk egyidejűleg választ kapni, amely az összköltséget és az időigényt csökkenti. Az általunk ismertetett tesztek a MammaPrint, Oncotype DX, BLN Assay, Theros Breast Cancer Index SM, MapQuant DX, ARUP Breast Bioclassifier, Celera Metastatic Score, eXagen BCtm, Invasive Gene Signature, Wound Response Indicator, Mammostrat, amelyek microarray vagy RT-PCR módszert alkalmaznak a génexpresszió mérésére. Ezek közül kettő (Oncotype DX és MammaPrint) már most az ajánlott diagnosztikus protokollok része. Ma még sok probléma jelentkezik a kereskedelmi forgalomban is kapható tesztekkel kapcsolatban: jellemző a gyenge validáltság, az azonos célra tervezett chipek teljesen eltérő génlistái, az eljárás költségessége és a kiértékeléshez szükséges bioinformatikai módszerek bonyolultsága.

  • 1 Al-Hajj, M, Wicha, MS, Benito-Hernandez, A et al. 2003 Prospective identification of tumorigenic breast cancer cells Proc Natl Acad Sci USA 100 39833988.

    • Search Google Scholar
    • Export Citation
  • 2 Andre, F, Hatzis, C, Anderson, K et al. 2007 Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer Clin Cancer Res 13 20612067.

    • Search Google Scholar
    • Export Citation
  • 3 Ayers, M, Symmans, WF, Stec, J et al. 2004 Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer J Clin Oncol 22 22842293.

    • Search Google Scholar
    • Export Citation
  • 4 Bardou, VJ, Arpino, G, Elledge, RM et al. 2003 Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases J Clin Oncol 21 19731979.

    • Search Google Scholar
    • Export Citation
  • 5 Bast, RC, Jr, Hortobagyi, GN 2004 Individualized care for patients with cancer – a work in progress N Engl J Med 351 28652867.

  • 6 Berry, DA, Cirrincione, C, Henderson, IC et al. 2006 Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 16581667.

    • Search Google Scholar
    • Export Citation
  • 7 Bhat, KM, Setaluri, V 2007 Microtubule-associated proteins as targets in cancer chemotherapy Clin Cancer Res 13 28492854.

  • 8 Bieche, I, Lidereau, R 1995 Genetic alterations in breast cancer Genes Chromosomes Cancer 14 227251.

  • 9 Blumencranz, P, Whitworth, PW, Deck, K et al. 2007 Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors Am J Surg 194 426432.

    • Search Google Scholar
    • Export Citation
  • 10 Broyde, A, Boycov, O, Strenov, Y et al. 2009 Role and prognostic significance of the Ki-67 index in non-Hodgkin’s lymphoma Am J Hematol 84 338343.

    • Search Google Scholar
    • Export Citation
  • 11 Bueno-de-Mesquita, JM, Linn, SC, Keijzer, R et al. 2009 Validation of 70-gene prognosis signature in node-negative breast cancer Breast Cancer Res Treat 117 483495.

    • Search Google Scholar
    • Export Citation
  • 12 Carter, P, Presta, L, Gorman, CM et al. 1992 Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 42854289.

    • Search Google Scholar
    • Export Citation
  • 13 Chang, HY, Nuyten, DS, Sneddon, JB et al. 2005 Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival Proc Natl Acad Sci USA 102 37383743.

    • Search Google Scholar
    • Export Citation
  • 14 Chang, HY, Sneddon, JB, Alizadeh, AA et al. 2004 Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds PLoS Biol 2 E7.

    • Search Google Scholar
    • Export Citation
  • 15 Cheang, MC, Voduc, D, Bajdik, C et al. 2008 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clin Cancer Res 14 13681376.

    • Search Google Scholar
    • Export Citation
  • 16 Davis, LM, Harris, C, Tang, L et al. 2007 Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma J Mol Diagn 9 327336.

    • Search Google Scholar
    • Export Citation
  • 17 Debatin, KM, Krammer, PH 2004 Death receptors in chemotherapy and cancer Oncogene 23 29502966.

  • 18 Drach, J, Gattringer, C, Glassl, H et al. 1992 The biological and clinical significance of the Ki-67 growth fraction in multiple myeloma Hematol Oncol 10 125134.

    • Search Google Scholar
    • Export Citation
  • 19 Duffy, MJ 2005 Predictive markers in breast and other cancers: a review Clin Chem 51 494503.

  • 20 Duffy, MJ, McCarthy, K 1998 Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review) Int J Oncol 12 13431348.

    • Search Google Scholar
    • Export Citation
  • 21 Dvorak, HF 1986 Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing N Engl J Med 315 16501659.

    • Search Google Scholar
    • Export Citation
  • 22 Fan, C, Oh, DS, Wessels, L et al. 2006 Concordance among gene-expression-based predictors for breast cancer N Engl J Med 355 560569.

  • 23 Fodor, SP, Rava, RP, Huang, XC et al. 1993 Multiplexed biochemical assays with biological chips Nature 364 555556.

  • 24 Gennari, A, Sormani, MP, Pronzato, P et al. 2008 HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials J Natl Cancer Inst 100 1420.

    • Search Google Scholar
    • Export Citation
  • 25 Gerdes, J, Schwab, U, Lemke, H et al. 1983 Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation Int J Cancer 31 1320.

    • Search Google Scholar
    • Export Citation
  • 26 Glas, AM, Floore, A, Delahaye, LJ et al. 2006 Converting a breast cancer microarray signature into a high-throughput diagnostic test BMC Genomics 7 278.

    • Search Google Scholar
    • Export Citation
  • 27 Goetz, MP, Suman, VJ, Ingle, JN et al. 2006 A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen Clin Cancer Res 12 20802087.

    • Search Google Scholar
    • Export Citation
  • 28 Goldhirsch, A, Coates, AS, Gelber, RD et al. 2006 First--select the target: better choice of adjuvant treatments for breast cancer patients Ann Oncol 17 17721776.

    • Search Google Scholar
    • Export Citation
  • 29 Gong, Y, Yan, K, Lin, F et al. 2007 Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study Lancet Oncol 8 203211.

    • Search Google Scholar
    • Export Citation
  • 30 Gralow, JR, Burstein, HJ, Wood, W et al. 2008 Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease J Clin Oncol 26 814819.

    • Search Google Scholar
    • Export Citation
  • 31 Gyorffy, B, Gyorffy, A, Tulassay, Z 2005 A “multiple testing” problémája és a genomiális kísérletekre alkalmazott megoldások Orvosi Hetilap 146 559563.

    • Search Google Scholar
    • Export Citation
  • 32 Habel, LA, Shak, S, Jacobs, MK et al. 2006 A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients Breast Cancer Res 8 R25.

    • Search Google Scholar
    • Export Citation
  • 33 Harris, L, Fritsche, H, Mennel, R et al. 2007 American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 52875312.

    • Search Google Scholar
    • Export Citation
  • 34 Harvey, JM, Clark, GM, Osborne, CK et al. 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 14741481.

    • Search Google Scholar
    • Export Citation
  • 35 Hu, Z, Fan, C, Oh, DS et al. 2006 The molecular portraits of breast tumors are conserved across microarray platforms BMC Genomics 7 96.

  • 36 Iverson, AA, Gillett, C, Cane, P et al. 2009 A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimens J Mol Diagn 11 117130.

    • Search Google Scholar
    • Export Citation
  • 37 Iyer, VR, Eisen, MB, Ross, DT et al. 1999 The transcriptional program in the response of human fibroblasts to serum Science 283 8387.

    • Search Google Scholar
    • Export Citation
  • 38 Janicke, F, Prechtl, A, Thomssen, C et al. 2001 Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 J Natl Cancer Inst 93 913920.

    • Search Google Scholar
    • Export Citation
  • 39 Jansen, MP, Sieuwerts, AM, Look, MP et al. 2007 HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study J Clin Oncol 25 662668.

    • Search Google Scholar
    • Export Citation
  • 40 Jerevall, PL, Brommesson, S, Strand, C et al. 2008 Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome Breast Cancer Res Treat 107 225234.

    • Search Google Scholar
    • Export Citation
  • 41 Kakarala, M, Wicha, MS 2008 Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy J Clin Oncol 26 28132820.

    • Search Google Scholar
    • Export Citation
  • 42 Liu, R, Wang, X, Chen, GY et al. 2007 The prognostic role of a gene signature from tumorigenic breast-cancer cells N Engl J Med 356 217226.

    • Search Google Scholar
    • Export Citation
  • 43 Loi, S, Haibe-Kains, B, Desmedt, C et al. 2007 Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade J Clin Oncol 25 12391246.

    • Search Google Scholar
    • Export Citation
  • 44 Look, MP, Putten van, WL, Duffy, MJ et al. 2002 Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients J Natl Cancer Inst 94 116128.

    • Search Google Scholar
    • Export Citation
  • 45 Ma, XJ, Hilsenbeck, SG, Wang, W et al. 2006 The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer J Clin Oncol 24 46114619.

    • Search Google Scholar
    • Export Citation
  • 46 Ma, XJ, Salunga, R, Dahiya, S et al. 2008 A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer Clin Cancer Res 14 26012608.

    • Search Google Scholar
    • Export Citation
  • 47 Ma, XJ, Wang, Z, Ryan, PD et al. 2004 A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen Cancer Cell 5 607616.

    • Search Google Scholar
    • Export Citation
  • 48 Mano, MS, Rosa, DD, De, AE et al. 2007 The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours Cancer Treat Rev 33 6477.

    • Search Google Scholar
    • Export Citation
  • 49 Mansel, RE, Goyal, A, Douglas-Jones, A et al. 2009 Detection of breast cancer metastasis in sentinel lymph nodes using intra-operative real time GeneSearch BLN Assay in the operating room: results of the Cardiff study Breast Cancer Res Treat 115 595600.

    • Search Google Scholar
    • Export Citation
  • 50 Miyabe, S, Okabe, M, Nagatsuka, H et al. 2009 Prognostic significance of p27Kip1, Ki-67, and CRTC1-MAML2 fusion transcript in mucoepidermoid carcinoma: a molecular and clinicopathologic study of 101 cases J Oral Maxillofac Surg 67 14321441.

    • Search Google Scholar
    • Export Citation
  • 51 Molina, R, Barak, V, Dalen van, A et al. 2005 Tumor markers in breast cancer – European Group on Tumor Markers recommendations Tumour Biol 26 281293.

    • Search Google Scholar
    • Export Citation
  • 52 Mook, S, Bonnefoi, H, Pruneri, G et al. 2009 Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial Eur J Cancer 45 12011208.

    • Search Google Scholar
    • Export Citation
  • 53 Mook, S, Schmidt, MK, Viale, G et al. 2009 The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study Breast Cancer Res Treat 116 295302.

    • Search Google Scholar
    • Export Citation
  • 54 Nielsen, TO, Hsu, FD, Jensen, K et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 53675374.

    • Search Google Scholar
    • Export Citation
  • 55 Onitilo, AA, Engel, JM, Greenlee, RT et al. 2009 Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival Clin Med Res 7 413.

    • Search Google Scholar
    • Export Citation
  • 56 Paik, S, Shak, S, Tang, G et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 28172826.

    • Search Google Scholar
    • Export Citation
  • 57 Paik, S, Tang, G, Shak, S et al. 2006 Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 37263734.

    • Search Google Scholar
    • Export Citation
  • 58 Parker, JS, Mullins, M, Cheang, MC et al. 2009 Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol 27 11601167.

    • Search Google Scholar
    • Export Citation
  • 59 Peintinger, F, Anderson, K, Mazouni, C et al. 2007 Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer Clin Cancer Res 13 40784082.

    • Search Google Scholar
    • Export Citation
  • 60 Perou, CM, Sorlie, T, Eisen, MB et al. 2000 Molecular portraits of human breast tumours Nature 406 747752.

  • 61 Ponti, D, Costa, A, Zaffaroni, N et al. 2005 Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties Cancer Res 65 55065511.

    • Search Google Scholar
    • Export Citation
  • 62 Pritchard, KI 2009 Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer? J Clin Oncol 27 38753876.

    • Search Google Scholar
    • Export Citation
  • 63 Rhodes, A, Jasani, B, Barnes, DM et al. 2000 Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems J Clin Pathol 53 125130.

    • Search Google Scholar
    • Export Citation
  • 64 Ring, BZ, Seitz, RS, Beck, R et al. 2006 Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer J Clin Oncol 24 30393047.

    • Search Google Scholar
    • Export Citation
  • 65 Ross, DT, Kim, CY, Tang, G et al. 2008 Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials Clin Cancer Res 14 66026609.

    • Search Google Scholar
    • Export Citation
  • 66 Ross, JS, Hatzis, C, Symmans, WF et al. 2008 Commercialized multigene predictors of clinical outcome for breast cancer Oncologist 13 477493.

    • Search Google Scholar
    • Export Citation
  • 67 Ross, JS, Symmans, WF, Pusztai, L et al. 2007 Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes Clin Cancer Res 13 28312835.

    • Search Google Scholar
    • Export Citation
  • 68 Rouzier, R, Rajan, R, Wagner, P et al. 2005 Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer Proc Natl Acad Sci USA 102 83158320.

    • Search Google Scholar
    • Export Citation
  • 69 Shi, L, Reid, LH, Jones, WD et al. 2006 The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements Nat Biotechnol 24 11511161.

    • Search Google Scholar
    • Export Citation
  • 70 Shipitsin, M, Campbell, LL, Argani, P et al. 2007 Molecular definition of breast tumor heterogeneity Cancer Cell 11 259273.

  • 71 Simon, JA, Szankasi, P, Nguyen, DK et al. 2000 Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae Cancer Res 60 328333.

    • Search Google Scholar
    • Export Citation
  • 72 Sorlie, T, Perou, CM, Tibshirani, R et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 1086910874.

    • Search Google Scholar
    • Export Citation
  • 73 Sotiriou, C, Neo, SY, McShane, LM et al. 2003 Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci USA 100 1039310398.

    • Search Google Scholar
    • Export Citation
  • 74 Sotiriou, C, Wirapati, P, Loi, S et al. 2006 Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis J Natl Cancer Inst 98 262272.

    • Search Google Scholar
    • Export Citation
  • 75 Steeg, PS, Zhou, Q 1998 Cyclins and breast cancer Breast Cancer Res Treat 52 1728.

  • 76 Straver, ME, Glas, AM, Hannemann, J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009.

    • Search Google Scholar
    • Export Citation
  • 77 Surowiak, P, Matkowski, R, Materna, V et al. 2005 Elevated metallothionein (MT) expression in invasive ductal breast cancers predicts tamoxifen resistance Histol Histopathol 20 10371044.

    • Search Google Scholar
    • Export Citation
  • 78 Symmans, WF, Peintinger, F, Hatzis, C et al. 2007 Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy J Clin Oncol 25 44144422.

    • Search Google Scholar
    • Export Citation
  • 79 Tanner, M, Isola, J, Wiklund, T et al. 2006 Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401 J Clin Oncol 24 24282436.

    • Search Google Scholar
    • Export Citation
  • 80 Tsai, CM, Chang, KT, Wu, LH et al. 1996 Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines Cancer Res 56 206209.

    • Search Google Scholar
    • Export Citation
  • 81 Tutt, A, Ashworth, A 2008 Can genetic testing guide treatment in breast cancer Eur J Cancer 44 27742780.

  • 82 Tutt, A, Wang, A, Rowland, C et al. 2008 Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature BMC Cancer 8 339.

    • Search Google Scholar
    • Export Citation
  • 83 Ueda, T, Aozasa, K, Tsujimoto, M et al. 1989 Prognostic significance of Ki-67 reactivity in soft tissue sarcomas Cancer 63 16071611.

  • 84 Veer van ‘t, LJ, Dai, H, Vijver van de, MJ et al. 2003 Expression profiling predicts outcome in breast cancer Breast Cancer Res 5 5758.

    • Search Google Scholar
    • Export Citation
  • 85 Vijver van de, M, He, YD, Veer van ‘t, LJ et al. 2002 A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 19992009.

    • Search Google Scholar
    • Export Citation
  • 86 Weigelt, B, Hu, Z, He, X et al. 2005 Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer Cancer Res 65 91559158.

    • Search Google Scholar
    • Export Citation
  • 87 Wiechmann, L, Sampson, M, Stempel, M et al. 2009 Presenting features of breast cancer differ by molecular subtype Ann Surg Oncol 16 27052710.

    • Search Google Scholar
    • Export Citation
  • 88 Wiesner, FG, Magener, A, Fasching, PA et al. 2009 Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients Breast 18 135141.

    • Search Google Scholar
    • Export Citation

Magyar Onkológia
Language Hungarian
Size  
Year of
Foundation
1956
Publication
Programme
 
Volumes
per Year
 
Issues
per Year
 
Founder Magyar Onkológusok Társasága
Founder's
Address
H-1122 Budapest, Hungary Ráth György u. 7-9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0025-0244 (Print)
ISSN 2060-0399 (Online)